Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by stock38on Jun 01, 2021 5:09am
258 Views
Post# 33301482

Taimed's Conference May 31 of 2021

Taimed's Conference May 31 of 2021Dear All
 
Taimed just held a conference on May 31 and their CEO disclosed something which might interest you. I summarize them as follows :
1. There are around 400 patients using Trogarzo currently and 
    the figure might reach 1500 at peak. If my memory is correct
    Spceo already predicted such long before.
2. No single one new patient increased in the year of 2021
    because of pandemic.
3. Thera. sacked all the sales staff in 2021 and changed their
    sales strategy from  focusing on the bars ( hanging some
    advertisement posts there) to reaching the KOL and
    physicians directly.
4. Taimed is very disappointed with the present sales of Trogarzo.
5. Regarding IV push:
    All patients will be enrolled in July and wish can apply to
    FDA for label extension in September of 2021.
6. Regarding IM push: Will enroll all patients within 6 to nine
    months and try to apply to FDA for label extension in the latte
    r half of 2022. The cost of this project is around 3 millions US
    dollars which will be covered by Thera.
And Taimeds just disclosed the sales volumes of May which is 5.2 millions NT dollars.

Thanks for your attention
 
  Stock from Taiwan

<< Previous
Bullboard Posts
Next >>